Jefferies Financial Group Reaffirms “Buy” Rating for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reaffirmed by investment analysts at Jefferies Financial Group in a report released on Tuesday,Digital Look reports. They presently have a £180 target price on the biopharmaceutical company’s stock. Jefferies Financial Group’s target price indicates a potential upside of 32.68% from the company’s current price.

Other equities research analysts have also issued research reports about the stock. Deutsche Bank Aktiengesellschaft restated a “sell” rating and issued a £115 target price on shares of AstraZeneca in a research note on Tuesday, June 2nd. Citigroup upped their price objective on shares of AstraZeneca from £170 to £180 and gave the company a “buy” rating in a report on Friday, April 10th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of £153.33.

AstraZeneca Price Performance

Shares of AstraZeneca stock opened at £135.66 on Tuesday. The firm has a market cap of £210.39 billion, a PE ratio of 20.43, a P/E/G ratio of 0.86 and a beta of 0.21. The business has a 50-day moving average price of £141.96 and a 200 day moving average price of £141.42. AstraZeneca has a twelve month low of £101.03 and a twelve month high of £157.32. The company has a quick ratio of 0.59, a current ratio of 0.91 and a debt-to-equity ratio of 71.66.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.